Important message regarding the discontinuation of Namenda® (memantine HCl) tablets: The general sale and distribution of Namenda tablets will be discontinued [date]. The oral solution of Namenda will continue to be broadly available, along with once-daily NAMENDA XR® (memantine HCl) extended release capsules.
[NAMENDA tablets will be available exclusively from Foundation Care, based on physician’s indication of medical need for twice-daily tablet formulation. Patients and Caregivers: Please talk to your healthcare provider to see if Namenda XR is an option for you or your loved one. HCPs: For patients who you determine have medical need for twice daily NAMENDA tablets, Foundation Care Pharmacy is the exclusive distributor. Please click here to download the form below and fax it to 1-844-572-0970 to request NAMENDA tablets for your patient. ]
Thank you for visiting an Actavis Web site. The information provided on this site is merely for educational purposes and its accuracy is not guaranteed. Do not use this site as a substitute for medical care or medical advice. Please consult with your physician or other medical care provider regarding any medical questions you may have.
The information, documents and graphic depictions (the "Information") published on this Web site are the property of Actavis plc and its subsidiaries and affiliates (collectively "Actavis"). Actavis assumes no responsibility for errors or omissions in the Information on this Web site. In no event shall Actavis be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. Actavis reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.
Except as provided in this paragraph, no license or right, express or implied, is granted to any person under any patent, trademark, trade dress or other proprietary right. Actavis grants a limited right to use the Information provided that the Information is not modified in any way and is used for informational and non-commercial personal use, and provided that Actavis’ copyright notice appears on any copies.
INFORMATION ON THIS WEB SITE IS PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.
Products described on this Web site may not be available in all countries or may be available under different names, in different strengths or formulations, or for different indications. Many of the pharmaceutical products described on this Web site are available only by prescription. Actavis is not engaged in the practice of rendering medical advice, and nothing on this site should be construed as recommending any pharmaceutical product for a particular use.
The Securities and Exchange Commission (SEC) encourages companies to disclose forward looking information so that investors can better understand a company's future prospects and make informed investment decisions. Due to changing market conditions, product competition, the nature of product development and regulatory approval processes, the achievement of forward looking statements contained in the Actavis Pharmaceutical Web site are subject to risks and uncertainties. For further details and a discussion of these risks and uncertainties, see Actavis' SEC filings, including its annual report on Form 10-K.
A link from this Web site to a non-Actavis Web site does not constitute an endorsement of the products or services offered by the non-Actavis Web site.
There is no evidence that NAMENDA prevents or slows the underlying disease process in patients with Alzheimer's disease.
IMPORTANT RISK INFORMATION FOR NAMENDA
Who should NOT take NAMENDA?
NAMENDA should not be taken by anyone who is allergic (hypersensitive) to memantine, the active substance in NAMENDA, or who has had a bad reaction to NAMENDA or any of its ingredients.
What should be discussed with the healthcare provider before taking NAMENDA?
Before starting NAMENDA, talk to the healthcare provider about all of the patient's past and present medical conditions, including:
- Seizure disorders
- Difficulty passing urine
- Liver, kidney or bladder problems
If the patient is taking other medications (including those without a prescription), ask the healthcare provider if NAMENDA is right for the patient.
- Certain medications, changes in diet, or medical conditions may affect the amount of NAMENDA in the body and possibly increase side effects.
What are the possible side effects of NAMENDA?
The most common side effects associated with NAMENDA treatment are dizziness, confusion, headache, and constipation. This is not a complete list of side effects.
Please see full Prescribing Information.